321 related articles for article (PubMed ID: 25017687)
1. Hypersensitivity from intravenous iron products.
Bircher AJ; Auerbach M
Immunol Allergy Clin North Am; 2014 Aug; 34(3):707-23, x-xi. PubMed ID: 25017687
[TBL] [Abstract][Full Text] [Related]
2. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
[TBL] [Abstract][Full Text] [Related]
3. A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts.
Demir S; Olgac M; Unal D; Gelincik A; Colakoglu B; Buyukozturk S
Int Arch Allergy Immunol; 2014; 165(2):100-3. PubMed ID: 25402762
[TBL] [Abstract][Full Text] [Related]
4. Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate.
Sane R; Baribeault D; Rosenberg CL
Pharmacotherapy; 2007 Apr; 27(4):613-5. PubMed ID: 17381390
[TBL] [Abstract][Full Text] [Related]
5. Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC; Geisser P
Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
[TBL] [Abstract][Full Text] [Related]
6. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management.
Rampton D; Folkersen J; Fishbane S; Hedenus M; Howaldt S; Locatelli F; Patni S; Szebeni J; Weiss G
Haematologica; 2014 Nov; 99(11):1671-6. PubMed ID: 25420283
[TBL] [Abstract][Full Text] [Related]
7. A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.
Coppol E; Shelly J; Cheng S; Kaakeh Y; Shepler B
Ann Pharmacother; 2011 Feb; 45(2):241-7. PubMed ID: 21304025
[TBL] [Abstract][Full Text] [Related]
8. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose.
Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D
J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271
[TBL] [Abstract][Full Text] [Related]
9. Nitrosative Stress and Apoptosis by Intravenous Ferumoxytol, Iron Isomaltoside 1000, Iron Dextran, Iron Sucrose, and Ferric Carboxymaltose in a Nonclinical Model.
Toblli JE; Cao G; Giani JF; Dominici FP; Angerosa M
Drug Res (Stuttg); 2015 Jul; 65(7):354-60. PubMed ID: 25050519
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA).
Neiser S; Koskenkorva TS; Schwarz K; Wilhelm M; Burckhardt S
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27455240
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications.
Jahn MR; Andreasen HB; Fütterer S; Nawroth T; Schünemann V; Kolb U; Hofmeister W; Muñoz M; Bock K; Meldal M; Langguth P
Eur J Pharm Biopharm; 2011 Aug; 78(3):480-91. PubMed ID: 21439379
[TBL] [Abstract][Full Text] [Related]
12. Rapid desensitization for hypersensitivity reactions to medications.
Castells M
Immunol Allergy Clin North Am; 2009 Aug; 29(3):585-606. PubMed ID: 19563999
[TBL] [Abstract][Full Text] [Related]
13. [Parenteral iron therapy: problems and possible solutions].
Hoigné R; Breymann C; Künzi UP; Brunner F
Schweiz Med Wochenschr; 1998 Apr; 128(14):528-35. PubMed ID: 9592894
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017.
Ehlken B; Nathell L; Gohlke A; Bocuk D; Toussi M; Wohlfeil S
Drug Saf; 2019 Mar; 42(3):463-471. PubMed ID: 30535629
[TBL] [Abstract][Full Text] [Related]
15. Intravenous iron sucrose: an alternative for oral iron in pregnancy with iron deficiency anemia.
Shi Q; Li J; Yao Q; Mi C; Yang J; Xing A
Ann Hematol; 2015 Mar; 94(3):523-5. PubMed ID: 25123238
[No Abstract] [Full Text] [Related]
16. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial.
Van Wyck DB; Martens MG; Seid MH; Baker JB; Mangione A
Obstet Gynecol; 2007 Aug; 110(2 Pt 1):267-78. PubMed ID: 17666600
[TBL] [Abstract][Full Text] [Related]
17. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
[TBL] [Abstract][Full Text] [Related]
18. The available intravenous iron formulations: History, efficacy, and toxicology.
Auerbach M; Macdougall I
Hemodial Int; 2017 Jun; 21 Suppl 1():S83-S92. PubMed ID: 28371203
[TBL] [Abstract][Full Text] [Related]
19. Hypersensitivity reactions and deaths associated with intravenous iron preparations.
Bailie GR; Clark JA; Lane CE; Lane PL
Nephrol Dial Transplant; 2005 Jul; 20(7):1443-9. PubMed ID: 15855210
[TBL] [Abstract][Full Text] [Related]
20. Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: a randomized trial.
Froessler B; Cocchiaro C; Saadat-Gilani K; Hodyl N; Dekker G
J Matern Fetal Neonatal Med; 2013 May; 26(7):654-9. PubMed ID: 23130909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
